Developer docs
API playgroundTry for free, no card

Search company profiles

DotLab

Full company profile

uuid0000kl7

Namestring
DotLab
Legal namestring
Dot Laboratories, Inc.
Websiteurl
dotlab.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

DotLab (Dot Laboratories, Inc.) is a women's healthcare technology company founded in 2016-2017 by CEO Heather Bowerman, headquartered in San Francisco, California, with a clinical laboratory in Branford, Connecticut. The company develops and commercializes diagnostic tests for endometriosis, a condition affecting approximately 200 million women globally and historically requiring laparoscopic surgery for diagnosis. DotLab's sole commercial product, DotEndo, is a non-invasive blood test that applies proprietary machine learning algorithms to differential expression levels of endometriosis-specific microRNA biomarkers to deliver a dichotomous diagnostic result via a physician portal within approximately ten days. The test demonstrated high accuracy (AUC 0.94) in clinical validation published in the American Journal of Obstetrics & Gynecology and is supported by ongoing data collection through the EMPOWER Study, a multi-center cohort study enrolling approximately 750 participants across nine leading US academic medical centers.

DotLab operates as a clinical laboratory services business, generating revenue by performing the DotEndo test on blood samples ordered by healthcare providers. Distribution is exclusively B2B through gynecologists, reproductive endocrinologists, and endometriosis specialists, with patient specimens collected in-clinic or via direct-to-patient mail-in kits and processed at the company's CLIA-compliant laboratory in Branford. The company launched DotEndo commercially in 2021 on a limited basis to select healthcare providers and is in the early stages of broader market access expansion. Pricing is not publicly disclosed and is determined through healthcare system negotiations and insurance coverage pathways.

The company is venture-backed, having raised approximately $12.65 million across disclosed rounds, including a $10 million Series A in July 2019 led by strategic investor CooperSurgical (a Cooper Companies business unit) with participation from Tiger Global Management, Luxor Capital Group, and Wilson Sonsini Goodrich & Rosati, and a subsequent round in 2023 with Kapor Capital and Inclusive Ventures Lab. DotLab holds exclusive worldwide intellectual property rights for its microRNA endometriosis diagnostic technology and maintains HIPAA, HITECH, and CCPA compliance. Recognition includes the 2019 FierceMedTech Fierce 15 designation and a 2018 Readers' Digest Top Medical Breakthrough award.

Short descriptiontext

DotLab is a women's healthcare technology company that has developed DotEndo, a first-of-its-kind non-invasive blood test using microRNA biomarkers and machine learning to diagnose endometriosis, currently available to select US healthcare providers including gynecologists and reproductive endocrinologists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endometriosis diagnostic test, non-invasive blood test, women's health diagnostics, microRNA biomarker testing, fertility diagnostic services
Industry2 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Endometriosis Diagnostic Testing
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

DotLab generates revenue through its diagnostic laboratory test service. Healthcare providers order DotEndo tests which are performed in DotLab's clinical laboratory. The test involves blood sample collection, analysis using proprietary microRNA biomarker technology, and delivery of results through a physician portal within ten days.

dotlab.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1DotEndo
Description

A breakthrough, non-invasive blood test that aids in the diagnosis of active endometriosis by measuring microRNA biomarkers in the blood.

dotlab.com
Core offering1 text field

DotLab develops and provides DotEndo, a first-of-its-kind non-invasive blood test for the diagnosis of active endometriosis. The test analyzes proprietary microRNA biomarkers in a blood sample using a machine learning algorithm to deliver a dichotomous positive/negative result through a physician portal within approximately ten days, addressing a diagnostic gap historically requiring laparoscopic surgery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • AUC of 0.94 in clinical validation study for distinguishing endometriosis from other gynecologic pathologies
+2 more records
Product overview1 text field

DotLab is a women's healthcare technology company offering a single core product: DotEndo, a breakthrough non-invasive blood test for endometriosis diagnosis. DotEndo analyzes microRNA biomarkers in blood samples using a proprietary algorithmic approach to provide actionable diagnostic results, addressing a significant gap in women's healthcare where diagnosis has traditionally required invasive laparoscopic surgery.

Product and service1 record
1DotEndo
CategoryWomen's Health Diagnostics
Description

A first-of-its-kind non-invasive blood test that measures endometriosis-specific microRNA biomarkers and applies a proprietary multi-analyte algorithm to provide a positive/negative result indicating the presence or absence of active endometriosis. Designed to replace laparoscopic surgical diagnosis for healthcare providers (gynecologists, reproductive endocrinologists, endometriosis specialists) and to shorten the average 7-10 year diagnostic delay for their patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-01
Description

DotLab partnered with researchers at Yale University to evaluate the performance of the test relative to laparoscopy in patients with and without endometriosis across multiple clinical cohorts. Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, serves as a key collaborator and advisor.

2EMPOWER Study Clinical Sites
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-center collaboration with leading endometriosis centers across the US including: Academia of Women's Health and Endoscopic Surgery, MedStar Health, NewYork-Presbyterian/Columbia University Irving Medical Center, Penn Medicine, Penn State College of Medicine, Stanford Medicine, The Advanced Gynecologic Surgery Institute, University Hospitals in Cleveland, Ohio, and University of Pittsburgh Medical Center. These partnerships support the EMPOWER Study enrolling approximately 750 participants for clinical validation.

dotlab.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct peer focused on non-invasive women's health diagnostics, including ovarian cancer risk assessment. Comparable in business model (specialty lab offering biomarker-based tests to OB/GYNs) and target customer segment (gynecologists managing complex women's health conditions).

TypeDirect peer
Description

Direct peer operating a specialty clinical lab that performs non-invasive molecular diagnostics on blood samples, including reproductive health and women's health tests. Comparable in proprietary biomarker + algorithmic approach, B2B clinician channel, and CLIA lab operating model.

TypeBroad incumbent
Description

Established molecular diagnostics incumbent with proprietary biomarker tests ordered by clinicians. Comparable in specialty lab business model and proprietary IP-driven test menu, though Myriad operates at much larger scale across multiple indications including women's health (BRCAtesting).

TypeBroad incumbent
Description

Large women's health-focused diagnostics and medical device company with deep OB/GYN distribution relationships. Comparable as a women's health diagnostics incumbent serving gynecologists, though Hologic's portfolio spans imaging, surgical, and screening diagnostics rather than specialty molecular tests.

TypeBroad incumbent
Description

Global leader in women's health, fertility, and reproductive genomics, and DotLab's lead Series A investor. Comparable as the dominant distributor into the same OB/GYN and reproductive endocrinology channels DotLab targets, though CooperSurgical's core franchise is devices and IVF consumables rather than molecular diagnostics.

TypeEmerging player
Description

Women's health and reproductive diagnostics company developing novel molecular tests. Comparable in addressing unmet diagnostic needs in reproductive health and use of novel biomarkers, though Progenity has historically focused on prenatal and gastrointestinal applications.

TypeBroad incumbent
Description

Established genomic diagnostics company combining proprietary RNA-based biomarker technology with machine learning to develop specialty tests. Comparable in molecular biomarker + ML/algorithmic architecture and CLIA lab-based delivery model serving specialist physicians.

TypeBroad incumbent
Description

Major clinical reference laboratory offering thousands of diagnostic tests including specialty women's health panels. Comparable as a clinical lab infrastructure provider, though LabCorp operates at vastly larger scale and breadth, and could be a future channel partner or competitive threat for DotEndo.

TypeEmerging player
Description

Women's health biotech focused on reproductive medicine, including diagnostics and therapeutics for conditions like endometriosis and PCOS. Comparable in targeting endometriosis and unexplained infertility with novel biomarker/AI approaches, though Celmatix has expanded toward therapeutic development.

TypeBroad incumbent
Description

Genetic diagnostics company offering broad specialty molecular testing, including women's health and reproductive genetics. Comparable in proprietary diagnostic IP and B2B clinician-channel model, though Invitae operates across many indications with a focus on hereditary genetic testing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DotLab

Endometriosis Diagnostic Testingdotlab.com

DotLab is a women's healthcare technology company that has developed DotEndo, a first-of-its-kind non-invasive blood test using microRNA biomarkers and machine learning to diagnose endometriosis, currently available to select US healthcare providers including gynecologists and reproductive endocrinologists.

What DotLab does

DotLab (Dot Laboratories, Inc.) is a women's healthcare technology company founded in 2016-2017 by CEO Heather Bowerman, headquartered in San Francisco, California, with a clinical laboratory in Branford, Connecticut. The company develops and commercializes diagnostic tests for endometriosis, a condition affecting approximately 200 million women globally and historically requiring laparoscopic surgery for diagnosis. DotLab's sole commercial product, DotEndo, is a non-invasive blood test that applies proprietary machine learning algorithms to differential expression levels of endometriosis-specific microRNA biomarkers to deliver a dichotomous diagnostic result via a physician portal within approximately ten days. The test demonstrated high accuracy (AUC 0.94) in clinical validation published in the American Journal of Obstetrics & Gynecology and is supported by ongoing data collection through the EMPOWER Study, a multi-center cohort study enrolling approximately 750 participants across nine leading US academic medical centers.

DotLab operates as a clinical laboratory services business, generating revenue by performing the DotEndo test on blood samples ordered by healthcare providers. Distribution is exclusively B2B through gynecologists, reproductive endocrinologists, and endometriosis specialists, with patient specimens collected in-clinic or via direct-to-patient mail-in kits and processed at the company's CLIA-compliant laboratory in Branford. The company launched DotEndo commercially in 2021 on a limited basis to select healthcare providers and is in the early stages of broader market access expansion. Pricing is not publicly disclosed and is determined through healthcare system negotiations and insurance coverage pathways.

The company is venture-backed, having raised approximately $12.65 million across disclosed rounds, including a $10 million Series A in July 2019 led by strategic investor CooperSurgical (a Cooper Companies business unit) with participation from Tiger Global Management, Luxor Capital Group, and Wilson Sonsini Goodrich & Rosati, and a subsequent round in 2023 with Kapor Capital and Inclusive Ventures Lab. DotLab holds exclusive worldwide intellectual property rights for its microRNA endometriosis diagnostic technology and maintains HIPAA, HITECH, and CCPA compliance. Recognition includes the 2019 FierceMedTech Fierce 15 designation and a 2018 Readers' Digest Top Medical Breakthrough award.

DotLab firmographics

Firmographics
Name
DotLab
Legal name
Dot Laboratories, Inc.
Website
https://dotlab.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
DotLab is a women's healthcare technology company that has developed DotEndo, a first-of-its-kind non-invasive blood test using microRNA biomarkers and machine learning to diagnose endometriosis, currently available to select US healthcare providers including gynecologists and reproductive endocrinologists.
Ownership category
akta.pro rank

DotLab industry classification

Industry
Product category
Endometriosis Diagnostic Testing
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Endometriosis diagnostic test
  • Non-invasive blood test
  • Women's health diagnostics
  • MicroRNA biomarker testing
  • Fertility diagnostic services

Where DotLab is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DotLab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: DotLab generates revenue through its diagnostic laboratory test service. Healthcare providers order DotEndo tests which are performed in DotLab's clinical laboratory. The test involves blood sample collection, analysis using proprietary microRNA biomarker technology, and delivery of results through a physician portal within ten days.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

DotLab product offering

Product offering

Core offering

DotLab develops and provides DotEndo, a first-of-its-kind non-invasive blood test for the diagnosis of active endometriosis. The test analyzes proprietary microRNA biomarkers in a blood sample using a machine learning algorithm to deliver a dichotomous positive/negative result through a physician portal within approximately ten days, addressing a diagnostic gap historically requiring laparoscopic surgery.

Product overview

DotLab is a women's healthcare technology company offering a single core product: DotEndo, a breakthrough non-invasive blood test for endometriosis diagnosis. DotEndo analyzes microRNA biomarkers in blood samples using a proprietary algorithmic approach to provide actionable diagnostic results, addressing a significant gap in women's healthcare where diagnosis has traditionally required invasive laparoscopic surgery.

Differentiator

Problem solved

Functional benefit

Brands

  • DotEndo: A breakthrough, non-invasive blood test that aids in the diagnosis of active endometriosis by measuring microRNA biomarkers in the blood.

Products and services

  • DotEndo A first-of-its-kind non-invasive blood test that measures endometriosis-specific microRNA biomarkers and applies a proprietary multi-analyte algorithm to provide a positive/negative result indicating the presence or absence of active endometriosis. Designed to replace laparoscopic surgical diagnosis for healthcare providers (gynecologists, reproductive endocrinologists, endometriosis specialists) and to shorten the average 7-10 year diagnostic delay for their patients.

Quantifiable outcome

  • AUC of 0.94 in clinical validation study for distinguishing endometriosis from other gynecologic pathologies
  • +2 more outcomes

Companies that use DotLab

Customer profile

Segments3 records

Ideal customer profiles1 record

DotLab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

DotLab partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Yale UniversitycoreStrategic or Co-development Partner · 1 July 2019DotLab partnered with researchers at Yale University to evaluate the performance of the test relative to laparoscopy in patients with and without endometriosis across multiple clinical cohorts. Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, serves as a key collaborator and advisor.
  • EMPOWER Study Clinical SitescoreStrategic or Co-development PartnerMulti-center collaboration with leading endometriosis centers across the US including: Academia of Women's Health and Endoscopic Surgery, MedStar Health, NewYork-Presbyterian/Columbia University Irving Medical Center, Penn Medicine, Penn State College of Medicine, Stanford Medicine, The Advanced Gynecologic Surgery Institute, University Hospitals in Cleveland, Ohio, and University of Pittsburgh Medical Center. These partnerships support the EMPOWER Study enrolling approximately 750 participants for clinical validation.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

DotLab competitors and assessment

Company assessment

Direct peers

  • Aspira Women's Health: Direct peer focused on non-invasive women's health diagnostics, including ovarian cancer risk assessment. Comparable in business model (specialty lab offering biomarker-based tests to OB/GYNs) and target customer segment (gynecologists managing complex women's health conditions).
  • Natera: Direct peer operating a specialty clinical lab that performs non-invasive molecular diagnostics on blood samples, including reproductive health and women's health tests. Comparable in proprietary biomarker + algorithmic approach, B2B clinician channel, and CLIA lab operating model.

Broad incumbents

  • Myriad Genetics: Established molecular diagnostics incumbent with proprietary biomarker tests ordered by clinicians. Comparable in specialty lab business model and proprietary IP-driven test menu, though Myriad operates at much larger scale across multiple indications including women's health (BRCAtesting).
  • Hologic: Large women's health-focused diagnostics and medical device company with deep OB/GYN distribution relationships. Comparable as a women's health diagnostics incumbent serving gynecologists, though Hologic's portfolio spans imaging, surgical, and screening diagnostics rather than specialty molecular tests.
  • CooperSurgical: Global leader in women's health, fertility, and reproductive genomics, and DotLab's lead Series A investor. Comparable as the dominant distributor into the same OB/GYN and reproductive endocrinology channels DotLab targets, though CooperSurgical's core franchise is devices and IVF consumables rather than molecular diagnostics.
  • Veracyte: Established genomic diagnostics company combining proprietary RNA-based biomarker technology with machine learning to develop specialty tests. Comparable in molecular biomarker + ML/algorithmic architecture and CLIA lab-based delivery model serving specialist physicians.
  • LabCorp: Major clinical reference laboratory offering thousands of diagnostic tests including specialty women's health panels. Comparable as a clinical lab infrastructure provider, though LabCorp operates at vastly larger scale and breadth, and could be a future channel partner or competitive threat for DotEndo.
  • Invitae: Genetic diagnostics company offering broad specialty molecular testing, including women's health and reproductive genetics. Comparable in proprietary diagnostic IP and B2B clinician-channel model, though Invitae operates across many indications with a focus on hereditary genetic testing.

Emerging players

  • Progenity: Women's health and reproductive diagnostics company developing novel molecular tests. Comparable in addressing unmet diagnostic needs in reproductive health and use of novel biomarkers, though Progenity has historically focused on prenatal and gastrointestinal applications.
  • Celmatix: Women's health biotech focused on reproductive medicine, including diagnostics and therapeutics for conditions like endometriosis and PCOS. Comparable in targeting endometriosis and unexplained infertility with novel biomarker/AI approaches, though Celmatix has expanded toward therapeutic development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DotLab social profiles

Digital presence

DotLab compliance and trust

Trust signal

Compliance2 records

DotLab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DotLab leadership team

Management profile

Number of profiles

Profiles1 record

DotLab funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DotLab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DotLab

What does DotLab do?

DotLab develops and provides DotEndo, a first-of-its-kind non-invasive blood test for the diagnosis of active endometriosis. The test analyzes proprietary microRNA biomarkers in a blood sample using a machine learning algorithm to deliver a dichotomous positive/negative result through a physician portal within approximately ten days, addressing a diagnostic gap historically requiring laparoscopic surgery.

Is DotLab a public or private company?

DotLab is a private company. It is classified as venture growth investor backed and is currently operating.

When was DotLab founded?

DotLab was founded in 2017. It employs 1 to 10 people.

Where is DotLab based?

DotLab is headquartered in New York, United States, in the North America region.

How does DotLab make money?

One revenue line is on record: diagnostic Testing Services.

Who are DotLab's main competitors?

Direct peers on record are Aspira Women's Health and Natera. Broad incumbents are Myriad Genetics, Hologic, CooperSurgical, Veracyte, LabCorp and Invitae. Emerging players are Progenity and Celmatix.

Does DotLab have an API?

No public API is recorded for DotLab.

What industry is DotLab in?

DotLab's product category is Endometriosis Diagnostic Testing. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDotLab shares primary market research findings for its novel DotEndo™ testDotLab released primary market research findings indicating strong interest in its novel DotEndo™ test for endometriosis diagnosis among both patients and medical providers. The study showed that 96% of surveyed patients were interested in learning more about the test, while OB/GYNs highlighted an unmet need for a reliable, non-invasive diagnostic tool to triage patients early.Clinical Lab ProductsDotLab Gets Three Granted Patents for Non-Invasive Endometriosis TestsMedical diagnostics company DotLab announced that the U.S. Patent and Trademark Office has granted three key patents for its DotEndo test, a non-invasive diagnostic technology for endometriosis based on microRNA analysis and machine learning algorithms. The patented inventions were developed through the company's EMPOWER clinical study conducted at centers of excellence across the United States.PR NewswireDotLab announces three granted patents for its non-invasive test for endometriosis, DotEndo™DotLab announced that the United States Patent and Trademark Office has granted three key patents for its non-invasive endometriosis diagnostic test, DotEndo™, covering microRNA-based technology and proprietary machine learning algorithms. The patents (U.S. Patent Nos. 10,982,282, 11,220,713, and 11,315,660 B2) were developed based on data from the EMPOWER clinical study, described as the most robust prospective observational study of its type. The validation study was published in the American Journal of Obstetrics & Gynecology.PR NewswireDotLab's laboratory receives accreditation from College of American PathologistsDotLab, a molecular diagnostics company focused on women's health, has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent inspection of its laboratory. The CAP Laboratory Accreditation Program, which was initiated in the early 1960s, is recognized by the U.S. federal government as being equal-to or more-stringent-than the government's own inspection program. The accreditation examined the laboratory's records, quality control procedures, staff qualifications, equipment, facilities, safety programs, and overall management over the preceding two years.PR NewswireDotLab begins enrollment in a multi-center cohort study for its non-invasive test for endometriosisDotLab has initiated the EMPOWER Study, a multi-center cohort study aimed at supporting the development of a non-invasive test for the diagnosis of endometriosis, enrolling approximately 750 women of reproductive potential across several U.S. medical centers. The study, which began enrolling participants in February 2021, seeks to evaluate the accuracy of DotLab's microRNA approach compared to surgical standard care. The availability of non-invasive diagnostic tools could significantly reduce delays in endometriosis diagnosis and treatment.PR NewswireDotLab Announces Scientific Advisory BoardDotLab, a San Francisco-based healthcare technology company focused on women's health, announced the formation of a Scientific Advisory Board to provide guidance on developing its non-invasive test for endometriosis diagnosis. The SAB comprises key opinion leaders in women's health including clinical research experts, OB/GYN specialists, and reproductive endocrinology professionals. The company cited data published in the American Journal of Obstetrics & Gynecology demonstrating high accuracy of its microRNA approach, with the CEO noting that endometriosis diagnosis delays can extend up to 10 years.PR NewswireDotLab, a molecular diagnostics company, announces the publication of the clinical validation study for its non-invasive test for endometriosisDotLab announced the publication of its clinical validation study for a non-invasive endometriosis test in the American Journal of Obstetrics & Gynecology, achieving an AUC of 0.94 in differentiating endometriosis from other gynecologic pathologies across two independent sample sets. The test addresses a significant unmet need, as the current standard of care relies on laparoscopic surgery and has not meaningfully improved in over a century. DotLab holds exclusive worldwide IP rights to the technology and plans to commercialize the test while working with regulators.PR NewswireFierceMedTech names DotLab as one of its "Fierce 15" companies of 2019DotLab has been named by FierceMedTech as one of the 2019 Fierce 15, recognizing it as one of the most promising private medtech companies in the industry. The company has developed a non-invasive diagnostic test for endometriosis combining novel biomarkers with machine learning, targeting a condition that affects 10% of women worldwide with an average ten-year diagnostic delay. This marks FierceMedTech's 8th annual selection, with DotLab noted as the only women's health company recognized among the honorees.Pulse 2.0Women’s Personalized Medicine Company DotLab Closes $10 MillionDotLab, a women's health personalized medicine company, raised $10 million in Series A funding led by CooperSurgical, with participation from Tiger Global and Luxor Capital. The company's non-invasive endometriosis test targets a disease affecting 10% of women worldwide, with an average 10-year diagnosis delay. Funding will support clinical validation and market expansion.